文献速递糖尿病肥胖与代谢综合征

2型糖尿病孕妇二甲双胍与安慰剂暴露子代结局(MiTy Kids):MiTy随机对照试验的24个月随访

Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-02-03

MiTy Kids 是 MiTy 随机对照试验的随访研究,纳入2型糖尿病孕妇的子代,母亲孕期接受口服二甲双胍1000 mg每日两次或安慰剂,评估至24月龄的肥胖指标。24月龄时两组BMI Z评分与皮褶厚度总和无差异,二甲双胍暴露组男性6至24月龄BMI轨迹较高,总体数据对孕期使用二甲双胍令人安心。

要点

  • 24月龄时二甲双胍组与安慰剂组BMI Z评分无差异(0.84 vs 0.91,p=0.72)。
  • 24月龄时两组皮褶厚度总和无差异(23.0 mm vs 23.8 mm,p=0.31)。
  • 男性中两组BMI轨迹显著不同(p=0.048),二甲双胍组6至24月龄BMI较高。

核心结论

  • 子代在宫内暴露与未暴露于二甲双胍时人体测量学指标相似,总体数据对2型糖尿病女性孕期使用二甲双胍及其子代长期健康令人安心。

研究设计与样本

  • MiTy Kids 为 MiTy 随机对照试验的随访研究,纳入母亲孕期接受口服二甲双胍1000 mg每日两次或安慰剂的子代,照顾者与研究者对用药保持盲法,在3、6、12、18、24月龄进行人体测量。

主要发现

  • 465名合格儿童中283名(61%)纳入,来自加拿大和澳大利亚19个中心。
  • 24月龄平均BMI Z评分二甲双胍组0.84(SD 1.52)vs 安慰剂组0.91(SD 1.38),平均差0.07(95%CI -0.31至0.45),p=0.72。
  • 24月龄平均皮褶厚度总和二甲双胍组23.0 mm(SD 5.2)vs 安慰剂组23.8 mm(SD 5.4),平均差0.8 mm(95%CI -0.7至2.3),p=0.31。
  • 二甲双胍不是24月龄BMI Z评分的预测因素(平均差-0.01,95%CI -0.42至0.37,p=0.92)。
  • BMI轨迹总体无差异,但男性中按治疗分组轨迹显著不同(p=0.048),二甲双胍组6至24月龄BMI较高;2型糖尿病女性的子代较WHO参考人群约重1个SD。

临床怎么用

  • 作者认为,总体数据对2型糖尿病女性孕期使用二甲双胍及其子代长期健康令人安心。

局限性

  • 465名合格儿童中仅283名(61%)纳入随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin is increasingly being used during pregnancy, with potentially adverse long-term effects on children. We aimed to examine adiposity in children of women with type 2 diabetes from the Metformin in Women with Type 2 Diabetes in Pregnancy (MiTy) trial, with and without in-utero exposure to metformin, up to 24 months of age. METHODS: MiTy Kids is a follow-up study that included infants of women who participated in the MiTy randomised controlled trial, receiving either oral 1000 mg metformin twice daily or placebo. Caregivers and researchers remained masked to the type of medication (metformin or placebo) mothers received during their pregnancy. Anthropometric measurements, including weight, height, and skinfold thicknesses, were taken at 3, 6, 12, 18, and 24 months. At 24 months, linear regression was used to compare the BMI Z score and sum of skinfolds in the metformin versus placebo groups, adjusted for confounders. Fractional polynomials were used to assess growth trajectories. This study is registered with ClinicalTrials.gov, NCT01832181. FINDINGS: Of the 465 eligible children, 283 (61%) were included from 19 centres in Canada and Australia. At 24 months, there was no difference between groups in mean BMI Z score (0·84 [SD 1·52] with metformin vs 0·91 [1·38] with placebo; mean difference 0·07 [95% CI -0·31 to 0·45], p=0·72) or mean sum of skinfolds (23·0 mm [5·2] vs 23·8 mm [5·4]; mean difference 0·8 mm [-0·7 to 2·3], p=0·31). Metformin was not a predictor of BMI Z score at 24 months of age (mean difference -0·01 [95% CI -0·42 to 0·37], p=0·92). There was no overall difference in BMI trajectory but, in males, trajectories were significantly different by treatment (p=0·048); BMI in the metformin group was higher between 6 and 24 months. Children of women with type 2 diabetes were approximately 1 SD heavier than the WHO reference population. INTERPRETATION: Anthropometrics were similar in children exposed and those not exposed to metformin in utero; hence, overall, data are reassuring with regard to the use of metformin during pregnancy in women with type 2 diabetes and the long-term health of their children. FUNDING: Canadian Institute for Health Research.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Feig DS, Sanchez JJ, Murphy KE, et al. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. Lancet Diabetes Endocrinol. 2023. PMID: 36746160. doi:10.1016/S2213-8587(23)00004-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。